Skip to main content

REVIEW article

Oncol.Rev.
Sec. Oncology Reviews: Reviews
Volume 18 - 2024 | doi: 10.3389/or.2024.1496141

Cytoreductive Surgery (CRS) followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) applications in upper and lower gastrointestinal cancer, a review

Provisionally accepted
Denise Drittone Denise Drittone 1*Francesca Matilde Schipilliti Francesca Matilde Schipilliti 2Giulia Arrivi Giulia Arrivi 1Federica Mazzuca Federica Mazzuca 1*
  • 1 Oncology Unit, Department of Clinical and Molecular Medicine, Sant' Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy., Rome, Italy
  • 2 Azienda Sanitaria Locale Roma 5, Roma, Italy

The final, formatted version of the article will be published soon.

    Peritoneal metastases (PM) are the spread of tumor forms into the peritoneum as metastases from another organ. PM is a frequent condition in metastatic gastrointestinal cancer (colorectal, gastric, pancreatic, appendiceal, and cholangiocarcinoma); their presence confers a poor prognosis, reducing patient survival. The standard treatment consists of systemic chemotherapy according to current guidelines. In recent years, scientific evidence has shown how combined cytoreductive surgery (CRS) techniques followed by hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival in this patient population. Despite the results still obtained, using this combined technique is still under discussion. This review aims to highlight the benefits and limitations of this combined procedure, which is already widely used to treat peritoneal metastases in gynecological tumors.

    Keywords: Peritoneal metastasis (PM), Cytoreductive surgery (CRS), Hyperthermic intraperitoneal chemotherapy (hipec), Gastrointestinal Cancer (GI), CRC (colorectal cancer)

    Received: 13 Sep 2024; Accepted: 14 Nov 2024.

    Copyright: © 2024 Drittone, Schipilliti, Arrivi and Mazzuca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Denise Drittone, Oncology Unit, Department of Clinical and Molecular Medicine, Sant' Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy., Rome, Italy
    Federica Mazzuca, Oncology Unit, Department of Clinical and Molecular Medicine, Sant' Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy., Rome, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.